Skip to main content
Erschienen in: Clinical and Experimental Medicine 2/2018

30.09.2017 | Original Article

Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables

verfasst von: L. A. Bautista-Herrera, U. De la Cruz-Mosso, R. Morales-Zambrano, G. D. Villanueva-Quintero, J. Hernández-Bello, M. G. Ramírez-Dueñas, E. Martínez-López, L. M. Brennan-Bourdon, C. J. Baños-Hernández, J. F. Muñoz-Valle

Erschienen in: Clinical and Experimental Medicine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Psoriatic arthritis (PsA) is an autoimmune inflammatory disease associated with psoriasis. The cause of this pathology is still unknown, but research suggests the diseases are caused by a deregulated cytokine production. MIF is a cytokine associated with immunomodulation of Th1, Th2, and Th17 cytokine profiles in inflammatory diseases. Based on this knowledge, the aim of this study was to determine the association of MIF and TNFA expression with Th1, Th2, and Th17 cytokine profiles in serum levels of PsA patients. A cross-sectional study was performed in 50 PsA patients and 30 control subjects (CS). The cytokine profiles were quantified by BioPlex MagPix system and the mRNA expression levels by real-time PCR. TNFA mRNA expression was 138.81-folds higher in PsA patients than CS (p < 0.001). Regarding MIF mRNA expression, no significant differences were observed; however, a positive correlation was identified between MIF mRNA expression and PsA time of evolution (r = − 0.53, p = 0.009). An increase of Th1 (IFNγ: PsA = 37.1 pg/mL vs. CS = 17 pg/mL, p < 0.05; TNFα: PsA = 24.6 pg/mL vs. CS = 9.8 pg/mL, p < 0.0001) and Th17 cytokine profiles (IL-17: PsA = 6.4 pg/mL vs. CS = 2.7 pg/mL, p < 0.05; IL-22: PsA = 8.4 pg/mL vs. CS = 1.8 pg/mL, p < 0.001), were found in PsA patients. Th2 cytokines were not significantly different in both groups. In conclusion, a high expression of TNFA mRNA, as well as an increase of Th1 and Th17 cytokine profiles evaluated by IFNγ, TNFα, IL-17, and IL-22 cytokines, was observed in PsA patients.
Literatur
1.
Zurück zum Zitat Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Eng J Med. 2017;376:957–70.CrossRef Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Eng J Med. 2017;376:957–70.CrossRef
2.
Zurück zum Zitat Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):569–79.CrossRefPubMed Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):569–79.CrossRefPubMed
4.
Zurück zum Zitat Álvarez J, Peláez I, Sanin L, et al. Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. J Rheumatol. 2011;86:21–5. Álvarez J, Peláez I, Sanin L, et al. Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. J Rheumatol. 2011;86:21–5.
5.
Zurück zum Zitat Bowcok A, Krueger J. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;9:699–711.CrossRef Bowcok A, Krueger J. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;9:699–711.CrossRef
7.
Zurück zum Zitat Moll J, Wright V. Psoriatic arthritis. Sem Arthr Rheum. 1973;1:59–78. Moll J, Wright V. Psoriatic arthritis. Sem Arthr Rheum. 1973;1:59–78.
8.
Zurück zum Zitat Morales-Zambrano RA, Bautista-Herrera LA, De la Cruz-Mosso U, et al. Macrophage migration inhibitory factor (MIF) promoter polymorphisms (− 794 CATT5-8 and − 173 G > C) association with MIF and TNFα in psoratic arthritis. Int J Clin Exp Med. 2014;7(9):2605–14.PubMedPubMedCentral Morales-Zambrano RA, Bautista-Herrera LA, De la Cruz-Mosso U, et al. Macrophage migration inhibitory factor (MIF) promoter polymorphisms (− 794 CATT5-8 and − 173 G > C) association with MIF and TNFα in psoratic arthritis. Int J Clin Exp Med. 2014;7(9):2605–14.PubMedPubMedCentral
9.
Zurück zum Zitat Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.CrossRefPubMed Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.CrossRefPubMed
10.
Zurück zum Zitat Llamas Covarrubias MA, Valle Y, Navarro Hernández RE, et al. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int. 2012;32:2307–11.CrossRefPubMed Llamas Covarrubias MA, Valle Y, Navarro Hernández RE, et al. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int. 2012;32:2307–11.CrossRefPubMed
11.
Zurück zum Zitat Xue H, Yang Y, Zhang Y, et al. Macrophage migration inhibitory factor interacting with Th17 cells may be involved in the pathogenesis of autoimmune damage in Hashimoto´s Tiroiditis. Med Inflamm. 2015. doi:10.1155/2015/621072. Xue H, Yang Y, Zhang Y, et al. Macrophage migration inhibitory factor interacting with Th17 cells may be involved in the pathogenesis of autoimmune damage in Hashimoto´s Tiroiditis. Med Inflamm. 2015. doi:10.​1155/​2015/​621072.
12.
Zurück zum Zitat De la Cruz Mosso U, Bucala R, Palafox-Sánchez CA, et al. Macrophage migration inhibitory factor: association of − 794 CATT5-8 and − 173 G > C polymorphisms with TNF-α in systemic lupus erythematosus. Hum Immunol. 2014;75(5):433–9.CrossRef De la Cruz Mosso U, Bucala R, Palafox-Sánchez CA, et al. Macrophage migration inhibitory factor: association of − 794 CATT5-8 and − 173 G > C polymorphisms with TNF-α in systemic lupus erythematosus. Hum Immunol. 2014;75(5):433–9.CrossRef
13.
Zurück zum Zitat Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol. 2005;37(2):65–73. Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol. 2005;37(2):65–73.
14.
Zurück zum Zitat Stojanovic I, Cvjeticanin T, Lazaroski S, et al. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology. 2009;126(1):74–83.CrossRefPubMedPubMedCentral Stojanovic I, Cvjeticanin T, Lazaroski S, et al. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology. 2009;126(1):74–83.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Das R, Moss JE, Robinson E, et al. Role of macrophage migration inhibitory factor in the Th2 immune response to epicutaneous sensitization. J Clin Immunol. 2011;31(4):666–80.CrossRefPubMedPubMedCentral Das R, Moss JE, Robinson E, et al. Role of macrophage migration inhibitory factor in the Th2 immune response to epicutaneous sensitization. J Clin Immunol. 2011;31(4):666–80.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Taylor W, Gladman DD, Helliwel P, et al. Classification criteria for psotiatic arthritis: development a new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed Taylor W, Gladman DD, Helliwel P, et al. Classification criteria for psotiatic arthritis: development a new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed
17.
Zurück zum Zitat Belmonte-Serrano MA. Is the DAS28 the most adequate method to estimated activity in rheumatoid arthritis clinic considerations and simulations scenarios. Rheumatol Clin. 2008;4:183–90. Belmonte-Serrano MA. Is the DAS28 the most adequate method to estimated activity in rheumatoid arthritis clinic considerations and simulations scenarios. Rheumatol Clin. 2008;4:183–90.
18.
Zurück zum Zitat Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–9.CrossRefPubMed Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–9.CrossRefPubMed
19.
Zurück zum Zitat Livak KJ, Shmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2 − DDCT method. Methods. 2001;25(4):402–8.CrossRefPubMed Livak KJ, Shmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2 − DDCT method. Methods. 2001;25(4):402–8.CrossRefPubMed
20.
Zurück zum Zitat Michalak SA, Pietrzak A, Szpietowsky CJ, et al. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22(4):160–8. Michalak SA, Pietrzak A, Szpietowsky CJ, et al. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22(4):160–8.
21.
Zurück zum Zitat Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmune Rev. 2015;14(4):2686–92.CrossRef Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmune Rev. 2015;14(4):2686–92.CrossRef
22.
Zurück zum Zitat Gang X, Wei H. Expression levels of IL–17 and TNF–α in degenerated lumbar intervertebral discs and their correlation. Exp Ther Med. 2016;11(6):2333–40.CrossRef Gang X, Wei H. Expression levels of IL–17 and TNF–α in degenerated lumbar intervertebral discs and their correlation. Exp Ther Med. 2016;11(6):2333–40.CrossRef
23.
Zurück zum Zitat Gabr MA, Jing L, Sinclair SM. Interleukin-17 synergizes with IFNγ or TNFα to promote inflammatory mediator release and intercellular adhesion molecule-1 (ICAM-1) expression in human intervertebral disc cells. J Orthop Res. 2011;29(1):1–7.CrossRefPubMedPubMedCentral Gabr MA, Jing L, Sinclair SM. Interleukin-17 synergizes with IFNγ or TNFα to promote inflammatory mediator release and intercellular adhesion molecule-1 (ICAM-1) expression in human intervertebral disc cells. J Orthop Res. 2011;29(1):1–7.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Zaba LC, Cardinale I, Suárez Fariñas M, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–94.CrossRefPubMedPubMedCentral Zaba LC, Cardinale I, Suárez Fariñas M, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–94.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Raychaduri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;2:183–93.CrossRef Raychaduri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;2:183–93.CrossRef
27.
Zurück zum Zitat Eyerich K, Dimartino V, Cavani A, et al. IL-17 and IL-22 in immunity: driving protection and pathology. Eur J Immunol. 2017;47(4):607–14.CrossRefPubMed Eyerich K, Dimartino V, Cavani A, et al. IL-17 and IL-22 in immunity: driving protection and pathology. Eur J Immunol. 2017;47(4):607–14.CrossRefPubMed
28.
Zurück zum Zitat Mosmann TR, Coffman RL. Two types of murine T helper clones. Definition according to profiles of limphokine activities. J Immunol. 1986;136(7):2348–57.PubMed Mosmann TR, Coffman RL. Two types of murine T helper clones. Definition according to profiles of limphokine activities. J Immunol. 1986;136(7):2348–57.PubMed
29.
Zurück zum Zitat Pasparakis M, Haase I, Nestle F. Mechanism regulating skin immunity and inflammation. Nature. 2014;14:289–301. Pasparakis M, Haase I, Nestle F. Mechanism regulating skin immunity and inflammation. Nature. 2014;14:289–301.
30.
Zurück zum Zitat Hernandez-Bello J, Orego RE, Vazque VM. Aberrant expression of interleukin-10 in rheumatoid arthritis: relationship with IL10 haplotypes and autoantibodies. Cytokine. 2017;95:88–96.CrossRefPubMed Hernandez-Bello J, Orego RE, Vazque VM. Aberrant expression of interleukin-10 in rheumatoid arthritis: relationship with IL10 haplotypes and autoantibodies. Cytokine. 2017;95:88–96.CrossRefPubMed
31.
Zurück zum Zitat Hayashi M, Yanava K, Umezawa Y, et al. IL-10 producing regulatory B cells are decreased in patient with psoriasis. J Dermatol. 2016;81(2):93–100. Hayashi M, Yanava K, Umezawa Y, et al. IL-10 producing regulatory B cells are decreased in patient with psoriasis. J Dermatol. 2016;81(2):93–100.
32.
Zurück zum Zitat Wang YN, Zhang Y, Zhu Xian, et al. The beneficial effect of total glucosides of paeony of psoriathic arthritis links to circulating Tregs and Th1 Cell functions. Phyther Res. 2014;28:372–81.CrossRef Wang YN, Zhang Y, Zhu Xian, et al. The beneficial effect of total glucosides of paeony of psoriathic arthritis links to circulating Tregs and Th1 Cell functions. Phyther Res. 2014;28:372–81.CrossRef
33.
Zurück zum Zitat Dolcino M, Ottria A, Barbieri A. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One. 2015;10(6):e0128262.CrossRefPubMedPubMedCentral Dolcino M, Ottria A, Barbieri A. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One. 2015;10(6):e0128262.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Gais P, Tiedje C, Altmayr F, et al. TRIF Signaling stimulates translation of TNF-a mRNA via prolonged activation of MK2. J Immunol. 2010;184:5842–8.CrossRefPubMed Gais P, Tiedje C, Altmayr F, et al. TRIF Signaling stimulates translation of TNF-a mRNA via prolonged activation of MK2. J Immunol. 2010;184:5842–8.CrossRefPubMed
35.
Zurück zum Zitat Sullivan KE, Reddy ABM, Dietzmann K. Epigenetic regulation of tumor necrosis factor alpha. Mol Cel Biol. 2007;14:5147–60.CrossRef Sullivan KE, Reddy ABM, Dietzmann K. Epigenetic regulation of tumor necrosis factor alpha. Mol Cel Biol. 2007;14:5147–60.CrossRef
36.
Zurück zum Zitat Steinhoff M, Meinhardt A, Steinhoff A. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol. 1999;141:1061–6.CrossRefPubMed Steinhoff M, Meinhardt A, Steinhoff A. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol. 1999;141:1061–6.CrossRefPubMed
37.
Zurück zum Zitat Matia García I, Salgado Goytia L, Muñoz Valle JF, et al. Macrophage migration inhibitory factor promoter polymorphisms (− 794 catt5–8 a − 173 g > c): relationship with mRNA expression and soluble mif levels in young obese subjects. Dis Mark. 2015. doi:10.1155/2015/461208. Matia García I, Salgado Goytia L, Muñoz Valle JF, et al. Macrophage migration inhibitory factor promoter polymorphisms (− 794 catt5–8 a − 173 g > c): relationship with mRNA expression and soluble mif levels in young obese subjects. Dis Mark. 2015. doi:10.​1155/​2015/​461208.
38.
Zurück zum Zitat Meyer Siegler K. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J Interferon Cytokine Res. 2000;20:769–78.CrossRef Meyer Siegler K. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J Interferon Cytokine Res. 2000;20:769–78.CrossRef
39.
Zurück zum Zitat Onodera S, Hiroshi T, Kouji S, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine. 2015;1:052–6. Onodera S, Hiroshi T, Kouji S, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine. 2015;1:052–6.
40.
Zurück zum Zitat Kingsley Gh, Kowalzyc A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51(8):1368–77.CrossRef Kingsley Gh, Kowalzyc A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51(8):1368–77.CrossRef
41.
Zurück zum Zitat Roussou E, Bouraoui A. Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA. Eur J Rheumatol. 2017;4(1):1–10.CrossRefPubMedPubMedCentral Roussou E, Bouraoui A. Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA. Eur J Rheumatol. 2017;4(1):1–10.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Brennan-Bourdon LM, De la Cruz-Mosso U, Reyes-Castillo Z, et al. MIF and TNFa serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study. Immunopharmacol Immunotoxicol. 2015;37(2):207–13.CrossRefPubMed Brennan-Bourdon LM, De la Cruz-Mosso U, Reyes-Castillo Z, et al. MIF and TNFa serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study. Immunopharmacol Immunotoxicol. 2015;37(2):207–13.CrossRefPubMed
Metadaten
Titel
Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables
verfasst von
L. A. Bautista-Herrera
U. De la Cruz-Mosso
R. Morales-Zambrano
G. D. Villanueva-Quintero
J. Hernández-Bello
M. G. Ramírez-Dueñas
E. Martínez-López
L. M. Brennan-Bourdon
C. J. Baños-Hernández
J. F. Muñoz-Valle
Publikationsdatum
30.09.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 2/2018
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-017-0475-0

Weitere Artikel der Ausgabe 2/2018

Clinical and Experimental Medicine 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.